Document:

Exhibit

EXHIBIT 10.1

BANK OF HAWAII CORPORATION 2014 STOCK AND INCENTIVE PLAN

RESTRICTED STOCK GRANT AGREEMENT (PERFORMANCE BASED)
 (FEBRUARY 24, 2017)

This Restricted Stock Grant Agreement (“Agreement”) dated February 24, 2017 (“Grant Date”), between Bank of Hawaii Corporation, a Delaware corporation (“Company”), with its registered office at 130 Merchant Street, Honolulu, Hawaii 96813, and the executive of the Company or subsidiary of the Company (“Grantee”) who as of the Grant Date is an Eligible Person under the Bank of Hawaii Corporation 2014 Stock and Incentive Plan (“Plan”) and who is specified in the “Notice of 2017 Restricted Stock Grant (Performance Based)” (“Notice”) attached hereto.

1.    Grant   of   Restricted   Shares.   Effective   as   of   the   Grant   Date, the Human Resources and Compensation Committee of the Company’s Board of Directors (“Committee”) has granted to Grantee the number of shares of Restricted Stock (“Restricted Shares”) as specified in the Notice pursuant to the Plan. Forty-five percent (45%) of the Restricted Shares are hereby designated as “First Category Shares”, forty-five percent (45%) as “Second Category Shares”, and ten percent (10%) as “Third Category Shares”.

2.    Restrictions During Period of Restriction. The given category of Restricted Shares shall be subject to forfeiture by Grantee and shall be nontransferable until the “Period of Restriction” terminates as to such Restricted Shares. The Restricted Shares shall vest in Grantee upon termination of the Period of Restriction (to the extent that the Restricted Shares have not previously been forfeited). For purposes of this Agreement, the term “Period of Restriction” shall mean the period that commences on the Grant Date and terminates on the date of certification of achievement of service and financial performance objectives by the Committee (“Date of Certification”), as described in this Section 2 below (or which Period of Restriction otherwise terminates as provided in this Section 2 below). In the event the Committee's certification is completed after the close of the New York Stock Exchange on the actual date of such certification (i.e., the date of the Committee meeting), the Date of Certification shall be deemed to be, and the Period of Restriction shall instead terminate, on the next business day.

As described below, the Period of Restriction shall terminate based upon the level of achievement of specified financial performance criteria, where the First Category Shares shall be conditioned upon “Return on Equity”, the Second Category Shares shall be conditioned upon “Stock Price to Book Ratio”, and the Third Category Shares shall be conditioned upon “Tier 1 Capital Ratio” (“Financial Performance Criteria”). In this regard, the Period of Restriction shall terminate with respect to the “Applicable Vesting Percentage” of the First Category Shares and Second Category Shares, as the case may be, based upon the Company’s achievement of the respective Financial Performance Criteria in accordance with the following schedule:

	
		
	Return on Equity and Stock Price to Book Ratio

	Financial Performance Criteria-- Three Year Average Percentile Rank
	Applicable Vesting Percentage

	75th and Above (Maximum)
	100%

	62.5th - 74.9th
	75%

	50th - 62.49th 
	50%

	Below 50th
	0%

4815-0253-9843.2    1.

Further, the Period of Restriction shall terminate with respect to the “Applicable Vesting Percentage” of the Third Category Shares based upon the Company’s achievement of the respective Financial Performance Criteria in accordance with the following schedule:

	
		
	Tier 1 Capital Ratio

	Financial Performance Criteria-- Three Year Average Percentile Rank
	Applicable Vesting Percentage

	50th and Above (Maximum)
	100%

	Below 50th
	0%

For purposes of this Agreement, the terms “Return on Equity”, “Stock Price to Book Ratio”, and “Tier 1 Capital Ratio” (as defined by the Federal Reserve Bank) shall mean such terms as determined for the banks that comprise the S&P Supercomposite Regional Bank Index (where for the applicable year, Return on Equity shall be measured as of December 31 of such year, Tier 1 Capital Ratio shall be measured as of September 30 of such year, and Stock Price to Book Ratio shall be measured based on stock price as of December 31 and book value as of September 30 of such year). With respect to the given Financial Performance Criteria, the “Three Year Average Percentile” shall mean the Company’s  percentile  level  on  the S&P Supercomposite Regional Bank Index for the average of the numerical measures over the three years 2017, 2018, and 2019. The Financial Performance Criteria shall be determined based on references to measures and percentiles for the peer group banks that comprise the January 3, 2017, S&P Supercomposite Regional Bank Index (with peer group banks determined by excluding banks with assets >$50B).

a.    Termination of Period of Restriction For First Category Shares

The Period of Restriction shall terminate with respect to the amount equal to the Applicable Vesting Percentage multiplied by the First Category Shares, provided that: (i) the Committee shall have certified the Three Year Average Percentile level for the Company’s “Return on Equity” that corresponds to such Applicable Vesting Percentage; and (ii) Grantee is an Employee on the Date of Certification.

		
	b.
	Termination of Period of Restriction Second Category Shares

The Period of Restriction shall terminate with respect to the amount equal to the Applicable Vesting Percentage multiplied by the Second Category Shares, provided that: (i) the Committee shall have certified the Three Year Average Percentile level for the Company’s “Stock Price to Book Ratio” that corresponds to such Applicable Vesting Percentage; and (ii) Grantee is an Employee on the Date of Certification.

		
	c.
	Termination of Period of Restriction Third Category Shares

The Period of Restriction shall terminate with respect to the amount equal to the Applicable Vesting Percentage multiplied by the Third Category Shares, provided that:  (i) the Committee shall have certified the Three Year Average Percentile level for
the  Company’s  “Tier  1  Capital Ratio”  that  corresponds  to  such Applicable  Vesting Percentage; and (ii) Grantee is an Employee on the Date of Certification.

d.    Termination of Period of Restriction Upon Certain Terminations of Employment 

In addition to the termination of the Period of Restriction based on the achievement of the service and financial performance objectives as described in Sections 2.a-2.c above, the Period of Restriction shall terminate in connection with certain terminations of Grantee’s employment with the Company and its subsidiaries as described in this Section 2.d. Specifically, the Period of Restriction for all of the Restricted Shares shall terminate (to the extent that the Period of Restriction has not previously terminated or the Restricted Shares have not previously been forfeited) upon the occurrence of any of the following: (i) the death of Grantee; (ii) the Grantee ceasing to be an Employee due to “disability” within the meaning of  that  term  under Section 409A of the Internal Revenue Code of 1986, as amended (“Code”) and the regulations promulgated thereunder; or (iii) upon or after the occurrence of a “Change in Control” (within the meaning of Section 2.5 of the Bank of Hawaii Corporation Change- in-Control Retention Plan, 

4815-0253-9843.2    2.

restatement effective December 17, 2009 (“Change-in-Control Plan”)) either (A) Grantee’s employment with the Company and its subsidiaries is terminated by the Company without “Cause” (within the meaning of Section 2.4 of the Change-in-Control Plan) or (B) Grantee terminates employment with the Company and its subsidiaries for “Good Reason” (within the meaning of Section 2.15 of the Change-In- Control Plan).

e.    Committee Determinations; Section 162(m). The Committee shall certify whether the Financial Performance Criteria for the First Category Shares, Second Category Shares, and Third Category Shares have been achieved as soon as administratively practicable following the completion of the three year performance period ending December 31, 2019. To the extent that the satisfaction of the Financial Performance Criteria is certified, the Restricted Shares subject to vesting shall vest on the Date of Certification (i.e., the Period of Restriction shall be terminated on the Date of Certification). This Agreement shall be interpreted and administered in a manner consistent with the intent that the Restricted Shares granted hereunder comply with the requirements of the performance-based compensation exception under Code Section 162(m).

3.    Forfeiture of Unvested Restricted Shares. Restricted Shares as to which the Period of Restriction has not terminated shall be forfeited and transferred to the Company upon the first to occur of: (a) Grantee’s ceasing to be an Employee for any reason, whether voluntary or involuntary (other than for a termination of employment described in Section 2.d), and (b) the date the Committee determines the Financial Performance Criteria were not met (to the extent that the Restricted Shares do not become vested based on the Applicable Vesting Percentages). However, as described in Section 2 above with respect to the termination of the Period of Restriction on the Date of Certification, the Applicable Vesting Percentage of the given category of Restricted Shares shall not be forfeited, to the extent that: (a) with respect to such Applicable Vesting Percentage of such category of Restricted Shares, the Committee has certified that the corresponding Three Year Average Percentile level for such Applicable Vesting Percentage has been achieved; and (b) the Grantee is an Employee on the Date of Certification.  Grantee’s employment shall not be treated as terminated in the case of a transfer of employment within the Company and its subsidiaries or in the case of sick leave and other approved leaves of absence.

4.    Issuance of Shares; Registration; Withholding Taxes. Restricted Shares shall be issued in Grantee’s name, shall bear the restrictive legends as are required or deemed advisable by the Company under the provisions of any applicable law, and shall be held by the Company until  all  restrictions  lapse  or  such  shares  are  forfeited  as  provided  herein. The Company may postpone the issuance or delivery of the Shares until (a) the completion of registration or other qualification of such Shares or transaction under any state or federal law, rule or regulation, or any listing on any securities exchange, as the Company shall determine to be necessary or desirable; (b) the receipt by the Company of such written representations or other documentation as the Company deems necessary to establish compliance with all applicable laws, rules and regulations, including applicable federal and state securities laws and listing requirements, if any; and (c) the payment to the Company of any amount required by the Company to satisfy any federal, state or other governmental withholding tax requirements related to the issuance or delivery of the Shares. Grantee shall comply with any and all legal requirements relating to Grantee’s resale or other disposition of any Shares acquired under this Agreement.

5.    Share Adjustments. The number and kind of Restricted Shares or other property subject to this Agreement shall be subject to adjustment in accordance with Section 13 of the Plan.

6.    Rights as Shareholder. Unless otherwise provided herein, Grantee shall be entitled to all of the rights of a shareholder with respect to the Restricted Shares, including the right to vote such Shares and to receive dividends and other distributions (not including share adjustments as described in Section 5 above) payable with respect to such Shares from and after the Grant Date. Grantee’s rights as a shareholder shall terminate with respect to any Restricted Shares forfeited by Grantee.

7.    Employment Rights. Neither the Plan nor the granting of the Restricted Shares shall be a contract of employment of Grantee by the Company or any of its subsidiaries. Grantee may be discharged from employment at any time by the employing Company or subsidiary, subject to any employment contract that may otherwise apply to Grantee.

8.    Amendment. This Agreement may be amended by the Committee at any time based on its determination that the amendment is necessary or advisable in light of any addition to, or change in, the Code or regulations issued thereunder or any federal or state securities law or other law or regulation, or the Plan, or based on any discretionary authority of the Committee under  the  Plan.  Unless  necessary  or  advisable  due  to  a  change  in  law, any amendment to this Agreement which has a material adverse effect on the interest of Grantee under this Agreement shall be adopted only with the consent of Grantee.

4815-0253-9843.2    3.

9.    Section 83(b) Election. Grantee shall promptly deliver to the Company a copy of any election filed by Grantee in respect of the Restricted Shares pursuant to Code Section 83(b).

10.    Notices. Any notice or other communication made in connection with this Agreement shall be deemed duly given when delivered in person or mailed by certified or registered mail, return receipt requested, to Grantee at Grantee’s address shown on Company records or such other address designated by Grantee by similar notice, or to the Company at its then principal office, to the attention of the Corporate Secretary of the Company. Furthermore, such notice or other communication shall be deemed duly given when transmitted electronically to Grantee at Grantee’s electronic mail address shown on the Company records or, to the extent that Grantee is an active employee, through the Company’s intranet.

11.    Plan Governs. The Restricted Shares evidenced by this Agreement are subject to the terms and conditions of the Plan and of this Agreement. In case of conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall control. Capitalized terms used in this Agreement and not defined herein shall have the meaning assigned in the Plan unless the context indicates otherwise.

12.    Miscellaneous. This Agreement shall bind and benefit Grantee, the heirs, distributees and personal representative of Grantee, and the Company and its successors and assigns. This Agreement may be signed in counterparts, each of which shall be deemed an original, and said counterparts shall together constitute one and the same instrument. Capitalized terms not herein defined shall have the meanings prescribed to them under the Plan.

BY ACCEPTING THE RESTRICTED SHARES GRANTED UNDER THIS RESTRICTED STOCK GRANT AGREEMENT, GRANTEE AGREES TO ALL THE TERMS AND CONDITIONS DESCRIBED IN THIS AGREEMENT AND IN THE PLAN.

IN WITNESS WHEREOF, the Company has caused this Agreement to be signed on its behalf by the undersigned, thereunto duly authorized, effective as of the Date of Grant.

BANK OF HAWAII CORPORATION

		
	By___________________________________________________
	 MARK A. ROSSI

Its Vice Chairman
“Company”

Agreed and Accepted:

_____________________________________________________

“Grantee”

4815-0253-9843.2    4.DEBT
PURCHASE AGREEMENT

 

This
Debt Purchase Agreement (the “Agreement”) made as of this _17th day of February, 2017 by and between LG Capital Funding,
LLC (the “Seller”) and GHS Investments, LLC (the “Buyer”).

1.      
PURCHASE AND SALE OF THE CONVERTIBLE NOTE

 

Upon
the terms and conditions herein contained, at each Closing as hereinafter defined, the Seller hereby sells, assigns and transfers
to the Buyer and the Buyer agrees to purchase from the Seller the “Transferred Rights” of the Seller and all rights
thereto, free and clear of all liens, claims, pledges, mortgages, restrictions, obligations, security interests and encumbrances
of any kind, nature and description. Transferred Rights shall mean all rights with respect to $563,027.81 in principal, accrued
interest, and settlement premiums under those certain Convertible Promissory Notes (collectively, the "Notes") issued
to the Seller by Rich Pharmaceuticals, Inc. (“Borrower” or “Company”) in the principal face amounts as
outlined in Schedule 1 below. By its signatures hereto, the Borrower accepts the assignment of the Transferred Rights to Buyer
and agrees that Buyer may convert the Transferred Rights into shares of the Company’s common stock.

Schedule
1

	Principal	Date
    of Issuance	Present
    Balance with Interest, and settlement premiums
	$30,000
    "LG 1"	5/26/16
                                         8%

        Redeemable
        Convertible Note.
	$38,106.74
	$19,864.73
    "LG 2"	6/8/16
                                         - Originally issued to Typenex on 5/29/15 pursuant to a

        $362,500
        Note and

        $19,864.73
        assigned to LG on 6/6/2016.
	$26,558.87
	$84,250
    "LG 3"	6/10/16
                                         - 8%

        Redeemable
        Convertible Note.
	$134,213.71
	$29,117.91
    "LG 4"	6/23/16
    - Originally issued to Auctus on 3/9/15 and assigned to LG 6/23/16.	$44,432.65
	$56,000
    "LG 5"	6/24/16
    8% Convertible Redeemable Note.	$90,075.62
	$58,000
    "LG 6"	7/8/16
    8% Convertible Redeemable Note.	$92,453.59

    	 	1	 

    	 	 	 

    

 

	$32,000
    "LG 7"	10/31/16
                                         - 8%

        Convertible
        Redeemable Note.
	$49,799.01
	$56,000
    "LG 8"	11/17/16
    8% Back End Note.	$87,387.62

 

		2.	CONSIDERATION

 

The
"Purchase Price" for each "Assigned Portion" of the Notes shall be the Buyer’s payment to the Seller,
to be broken into four (4) monthly (31 calendar day) Tranches (each a "Tranche") as follows:

 

	Issuance
    Date	 

        Tranche
        1
	 

        Tranche
        2
	 

        Tranche
        3
	 

        Tranche
        4

	5/26/2016	38106.74	 	 	 
	6/8/2016	26558.87	 	 	 
	6/10/2016	 	134213.71	 	 
	6/23/2016	44432.65	 	 	 
	6/24/2016	 	 	 	90075.62
	7/8/2016	 	 	92453.59	 
	10/31/2016	 	 	49799.01	 
	11/17/2016	 	 	 	87387.62
		$
    109,098.26	$
    134,213.71	$
    142,252.60	$
    177,463.24

 

		3.	CLOSING

 

The
Closing of Tranche 1 contemplated by this Agreement shall take place no later than February 17 , 2017. Buyer shall only
obtain beneficial ownership over those Assigned Portions of the Transferred Rights for which Buyer has rendered payment to the
Seller. As long as Buyer has made timely payments in accordance with the Schedule above, the Seller shall not sell, convert or
in any way hypothecate unsold portions of the Notes.

The
closing of Tranche 2 shall take place no later than March 20, 2017. The closing of Tranche 3 should take place no later than April
20, 2017. The closing of Tranche 4 should take place no later than May 20, 2017. Buyer shall only obtain beneficial ownership
over those Assigned Portions of the Transferred Rights for which Buyer has rendered payment to the Seller. As long as Buyer has
made timely payments in accordance with the Schedule above, the Seller shall not sell, convert or in any way hypothecate unsold
portions of the Notes.

 

The
Seller presently has 2,522,517,897 authorized but unissued shares of the Company's stock in reserve for its benefit. Upon the
closing of Tranche 1, Seller shall authorize the release of 630,629,474 shares back to the treasury of the issuer for the
benefit of the Buyer. Seller shall subsequently release 630,629,474upon the closing of Tranche 2, to be

    	 	2	 

    	 	 	 

    

630,629,474
upon the closing of Tranche 3 and 630,629,474upon the closing of Tranche 4. A tranche must be closed and funded within
5 business days of the dates listed above or the Seller may terminate this Agreement. In the event the tranche in question is
not funded on the date specified above, the numbers may be revised by the Seller to reflect additional accrued interest

 

4.      
REPRESENTATIONS AND WARRANTIES OF SELLER The Seller hereby represents and warrants to the Buyer as follows:

 

4.1              
Status of the Seller and the Note. The Seller is the beneficial owner of the Notes, and the Notes are free and clear of
all mortgages, pledges, restrictions, liens, charges, encumbrances, security interests, obligations or other claims. The Notes
are currently outstanding and Seller is informed by Company that the Notes represent bona fide debt obligations of the Company.

 

4.2              
Authorization; Enforcement. (i) Seller has all requisite corporate power and authority to enter into and perform the Agreement
and to consummate the transactions contemplated hereby and to sell each Note, in accordance with the terms hereof, (ii) the execution
and delivery of this Agreement by the Seller and the consummation by it of the transactions contemplated hereby (including, without
limitation, the sale of the Note to the Buyer) have been duly authorized by the Seller and no further consent or authorization
of the Seller or its members is required, (iii) this Agreement has been duly executed and delivered by the Seller, and (iv) this
Agreement constitutes a legal, valid and binding obligation of the Seller enforceable against the Seller in accordance with its
terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies or by other equitable
principles of general application.

 

4.3              
No Conflicts. The execution, delivery and performance of this Agreement by the Seller and the consummation by the Seller
of the transactions contemplated hereby (including, without limitation, the sale of the Notes to the Buyer) will not (i) conflict
with or result in a violation of any provision of its certificate of formation or other organizational documents, or (ii) violate
or conflict with or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of
time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, note, bond, indenture or other instrument to which Seller are a party, or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations
of any self-regulatory organizations to which Seller are subject) applicable to Seller or the Note is bound or affected. The Seller
is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental
agency, regulatory agency, self-regulatory organization or stock market or any third party in order for it to execute, deliver
or perform any of its obligations under this Agreement in accordance with the terms hereof.

 

4.4              
Title; Rule 144 Matters. Seller has good and marketable title to the Notes, free and clear of all liens, restrictions,
pledges and encumbrances of any kind. Seller is not an “Affiliate” of the Company, as that term is defined in Rule
144 of the Securities Act of 1933, as amended (the “1933 Act”) and has not been an "Affiliate" for at least
Ninety (90) calendar days prior to the execution of this Agreement.

    	 	3	 

    	 	 	 

    

 

		4.5	Consent
                                         of the Company.

 

(i)                 
The Company, as evidence by its signature at the foot of this Agreement, hereby represents and warrants that, upon delivery to
the Company of the Notes, the Company shall promptly cause to be issued to and in the name of Buyer one of more new executed Notes
in the principal aggregate amount of equal to the face value of the Note. The Notes may contain the same restrictive legend as
provided in the original Note, but no stop transfer order. The Notes are currently outstanding in the entire amount stated and
represent bona fide debt obligations of the Company.

 

(ii)                
The signature by the Company also represents the Company’s agreement to treat Buyer as a party to, and having all the rights
of the Seller with respect to the Transferred Rights.

 

5.      
REPRESENTATIONS, WARRANTIES AND ACKNOWLEDGEMENTS OF THE BUYER. The Buyer hereby represents warrants and acknowledges
to the Seller as follows:

 

5.1              
Sophisticated Investor. The Buyer has sufficient knowledge and experience of financial and business matters, is able to
evaluate the merits and risks of the partial purchase of the Notes and has had substantial experience in previous private and
public purchases of securities. Buyer is an “accredited investor” within the meaning of Regulation D, Rule 501(a),
promulgated by the Securities and Exchange Commission under the Securities Act;

 

5.2              
Authorization; Enforcement. (i) Buyer has all requisite corporate power and authority to enter into and perform the Agreement
and to consummate the transactions contemplated hereby and to purchase each Note, in accordance with the terms hereof, (ii) the
execution and delivery of this Agreement by the Buyer and the consummation by it of the transactions contemplated hereby (including,
without limitation, the purchase of the Note by the Buyer) have been duly authorized by the Buyer and no further consent or authorization
of the Buyer or its members is required, (iii) this Agreement has been duly executed and delivered by the Buyer, and (iv) this
Agreement constitutes a legal, valid and binding obligation of the Buyer enforceable against the Buyer in accordance with its
terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies or by other equitable
principles of general application.

 

5.3              
No Conflicts. The execution, delivery and performance of this Agreement by the Buyer and the consummation by the Buyer
of the transactions contemplated hereby will not (i) conflict with or result in a violation of any provision of its certificate
of formation or other organizational documents, or (ii) violate or conflict with or result in a breach of any provision of, or
constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others
any rights of termination, amendment, acceleration or cancellation of, any agreement, note, bond, indenture or other instrument
to which Buyer is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal
and state securities laws and regulations and regulations of any self-regulatory organizations to which Buyer is subject) applicable
to Seller or the Note is bound or affected. The Buyer is not required to obtain any consent, authorization or order of, or make
any filing or registration with, any court, governmental agency, regulatory agency, self-regulatory organization or stock market
or any third party in order for it to execute, deliver or perform any of its obligations under this Agreement in accordance with
the terms hereof.

    	 	4	 

    	 	 	 

    

 

5.4              
Big Boy Acknowledgement. Buyer acknowledges that: (i) Seller may be, and Buyer is proceeding on the assumption that Seller
is, in possession of material, non-public information concerning the Company and its direct and indirect subsidiaries (the “Information”),
which is not or may not be known to Buyer and that Seller has not disclosed to Buyer; (ii) Buyer is voluntarily assuming all risks
associated with the purchase of the Notes and expressly warrants and represents that (x) except as otherwise stated or represented
herein, Seller has not made, and Buyer disclaims the existence of or its reliance on, any representation by Seller concerning
the Company or the Notes, and (y) Buyer is not relying on any disclosure or non-disclosure made or not made, or the completeness
thereof, in connection with or arising out of the purchase of the Note (except as otherwise stated or represented herein), and
therefore has no claims against the Seller with respect thereto; and (iii) Seller shall not have any liability, and Buyer waives
and releases any claim that it might have against Seller or any of its partners, representatives, agents and affiliates whether
under applicable securities law or otherwise, based on Seller’s knowledge, possession or nondisclosure to Buyer of the Information,
except for any representations or warranties of the Seller contained herein).

 

		6.	MISCELLANEOUS

 

6.1              
Binding Effect; Benefits. This Agreement shall inure to the benefit of, and shall be binding upon, the parties hereto and
their respective successors and permitted assigns. Except as otherwise set forth herein, this Agreement may not be assigned by
any party hereto without the prior written consent of the other party hereto. Except as otherwise set forth herein, nothing in
this Agreement, expressed or implied, is intended to confer on any person other than the parties hereto or their respective successors
and permitted assigns any rights, remedies, obligations or liabilities under or by any reason of this Agreement.

 

6.2              
Notices. All notices, requests, demands and other communications which are required to be or may be given under this Agreement
shall be in writing and shall be deemed to have been duly given when delivered in person, or transmitted by telecopy or telex,
or upon receipt after dispatch by certified or registered first class mail, postage prepaid, return receipt requested, to the
party to whom the same is so given or made, at the following addresses (or such others as shall be provided in writing hereafter):

 

		(a)	If
                                         to the Buyer to: GHS Investments LLC

200
Stonehinge Lane Suite 3

Carle
Place, NY 11514

Attn:
Sarfraz Hajee

    	 	5	 

    	 	 	 

    

 

		(b)	If
                                         to the Seller to:

LG
Capital Funding, LLC 1218 Union St, Suite #2

Brooklyn,
NY 11225

Attn:
Joseph Lerman 

 

6.3              
Entire Agreement. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings,
oral and written, between the parties hereto with respect to the subject matter hereof.

 

6.4              
Further Assurances. After the Closing of Tranche 1, at the request of either party, the other party shall execute, acknowledge
and deliver, without further consideration, all such further assignments, conveyances, endorsements, deeds, powers of attorney,
consents and other documents and take such other action as may be reasonably requested to consummate the transactions contemplated
by this Agreement.

 

6.5              
Headings. The section and other headings contained in this Agreement are for reference purposes only and shall not be deemed
to be part of this Agreement or to affect the meaning or interpretation of this Agreement.

 

6.6              
Counterparts. This Agreement may be executed in any number of counterparts and by facsimile, each of which, when executed,
shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.

 

6.7              
Governing Law. This Agreement shall be construed as to both validity and performance and enforced in accordance with and
governed by the laws of the State of New York, without giving effect to the conflicts of law principles thereof.

 

6.8              
Severability. If any term or provision of this Agreement shall to any extent be invalid or unenforceable, the remainder
of this Agreement shall not be affected thereby, and each term and provision of the Agreement shall be valid and enforced to the
fullest extent permitted by law.

 

6.9              
Amendments. This Agreement may not be modified or changed except by an instrument or instruments in writing executed by
the parties hereto.

    	 	6	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

 

BUYER:

GHS
Investments, LLC

 

 

By:
/s/ Authorized Signatory

Title:

 

SELLER:

 

LG
Capital Funding, LLC

 

By:
/s/ Authorized Signatory

Title:

 

ACCEPTED
AND AGREED:

 

Rich
Pharmaceuticals, Inc.

 

 

By:
/s/ Ben Chang

Title:
CEO

    	 	7	 

    	 	 	 

    

  

NON-AFFILIATION
LETTER

 

February
17, 2017

 

 

 

GHS
Investments, LLC Gentlemen:

Please
let this letter serve as confirmation that LG Capital Funding, LLC is not now, and has not been during the preceding 90 days,
an officer, director, 10% or more shareholder of Rich Pharmaceuticals, Inc. or in any other way an “affiliate” of
Rich Pharmaceuticals, Inc (as that term is defined in Rule 144(a) (1) adopted pursuant to the Securities Act of 1933, as amended).

 

Very
truly yours,

 

LG
CAPITAL FUNDING, LLC

 

 

/s/
Jospeh Lerman 

By:
Joseph Lerman, Manager

    	 	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]